News | February 23, 2015

UCLA Study Assesses Treatment Options for Men with Prostate Cancer

Results indicate radiation therapy most prescribed without consideration of risk factors

UCLA, prostate cancer, radiation therapy, study

February 23, 2015 — Researchers at the University of California Los Angeles (UCLA) have found that radiation therapy is the most common treatment for men with prostate cancer regardless of the aggressiveness of the tumor, risk to the patient and overall patient prognosis. These findings lay the groundwork for improved treatment assessment by physicians and to better inform men fighting the disease.

Led by UCLA Jonsson Comprehensive Cancer Center member Karim Chamie, M.D., the observational study analyzed the claims data of more than 37,000 patients from 2004 to 2007, provided by the Surveillance, Epidemiology and End Results (SEER) Program of the National Cancer Institute (NCI). The study was published online in the journal JAMA Oncology.

The research was conducted at UCLA, and Chamie's team found that radiation therapy was the most common treatment at 58 percent, followed by radical prostatectomy (a surgical procedure to remove the prostate) at 19 percent. Other treatments trailed at 10 percent, including watchful waiting (where doctors wait and see if cancer progresses before treating it) and active surveillance (when patients undergo routine biopsies, blood tests and magnetic resonance imaging [MRI] to determine if cancer is progressing and undergo active treatment).

Chamie and colleagues discovered that radiation was the most common treatment prescribed regardless of cancer stage, prostate-specific antigen (PSA) level, cancer grade or the life expectancy of the patient. The most significant predictor of a man receiving radiation therapy is a referral to a radiation oncologist. On the other hand, urologists and surgeons significantly incorporated the age and health of the patient as well as the aggressiveness of the cancer when recommending surgery.

"Doctors and patients view radiation as safe," said Chamie, associate professor of urology. "There's no anesthesia or hospitalization, the patient comes in for 15 or 20 minutes for their daily radiation treatment, it's localized to a specific area, then they get to go home. They often don't notice any immediate effects upfront."

But by two years after treatment, men often start to suffer side effects, said Chamie. These side effects may vary from being mild in nature to very severe.

If a patient has an aggressive prostate cancer and has a long life expectancy, then these side effects and risks may be significantly outweighed by the benefits of the radiation treatment. However, if a man with an indolent  prostate tumor and a limited life expectancy is treated with radiation therapy and suffers from these side effects during the twilight of his life, then he reaps no benefit and only suffers from the toxicity.

Chamie hopes these findings enlighten the public and allow physicians to make an informed decision when it comes to the best treatment option for men who may or may not benefit from radiation therapy in the long run.

"Men fighting this disease don't always need radiation or surgery as their only choice," said Chamie. "As we find more reports demonstrating the safety and efficacy of active surveillance, I hope patients and physicians look to this as the first treatment option for low-risk and indolent disease. Here at UCLA, I am proud to say that we have a robust active surveillance program that utilizes MRI and targeted biopsies to monitor and survey these indolent tumors."

For more information: www.cancer.ucla.edu

Related Content

Stronger Distribution Networks to Bolster Radiotherapy Patient Positioning Accessories
News | Patient Positioning Radiation Therapy | July 19, 2019
A recent study projects global market revenues for radiotherapy patient positioning accessories will exceed revenues of...
CMS Proposes New Alternative Payment Model for Radiation Oncology
News | Radiation Oncology | July 17, 2019
The Centers for Medicare and Medicaid Services (CMS) issued a proposal for an advanced alternative payment model (APM)...
AAPM 2019 Features More Than 40 Presentations on ViewRay's MRIdian MRI-guided Radiotherapy
News | Image Guided Radiation Therapy (IGRT) | July 16, 2019
ViewRay Inc. announced that the company's MRIdian System is the focus of more than 40 abstracts selected by the...
RaySearch Releases Version 3A of RayCare Oncology Information System
Technology | Oncology Information Management Systems (OIMS) | July 15, 2019
RaySearch has released RayCare 3A, a new version of the next-generation oncology information system (OIS). RayCare is...
IBA Launches Monte Carlo Patient QA for Varian Halcyon at AAPM 2019
Technology | Quality Assurance (QA) | July 10, 2019
IBA announced the launch of the latest functionality of the SciMoCa Monte Carlo Patient QA solution at the 61st annual...
Researchers Use Artificial Intelligence to Deliver Personalized Radiation Therapy
News | Radiation Therapy | July 09, 2019
New Cleveland Clinic-led research shows that artificial intelligence (AI) can use medical scans and health records to...
The Beamscan 3-D water phantom with the Varian Halcyon radiotherapy system

The Beamscan 3-D water phantom with the Varian Halcyon radiotherapy system. Image courtesy of PTW.

News | Quality Assurance (QA) | July 08, 2019
At this year’s American Association of Physicists in Medicine (AAPM) show, July 14-18 in San Antonio, Texas, PTW will...
Aktina Medical Partners With Elekta for Global Distribution of Interlocking SRS Cones
News | Radiation Therapy | July 05, 2019
Aktina Medical announced that Elekta Instrument AB, based in Sweden, will offer and distribute the Aktina line of...